Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Sep 30 | 2021Lilly Presents SURPASS-3 CGM and MRI Sub-studies; Insulet Omnipod 5 Extension Study Results; Onduo Collaborates with Fitbit; EASD 2021 Key Press Releases (Sept 30)Purchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Other Sep 29 | 2021Nemaura Launches New Metabolic Health Program; Biocon Receives More Form 483 Observations; Virta Health Key Leadership Appointments; Dexcom G6 Coverage in Manitoba; EASD 2021 Key Press Releases (Sept 29)Purchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring Sep 28 | 2021Lilly Cuts Non-branded Lispro Prices By 40%; Positive Ph1 Data for New GLP-1RA Asset; Lifescan Presents Tu Salud Trial Data in Hispanic Population; EASD 2021 Key Press Releases (Sept 28)Purchase Blast$599
Posted in: Glucose Monitoring, Insulin Delivery Sep 27 | 2021Biocorp and Novo Mallya Partnership; Nemaura Signs Contract for Non-invasive CGM EU Distribution; AHA Late-breaking Science Sessions Released; EASD 2021 Key Press Releases (Sept 27)Purchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Sep 23 | 2021New Non-invasive BGM; Amarin Updates Vascepa US Go-to-market Strategy; Welldoc Receives 510(k) Clearance for Bolus and Premixed Insulin Titration; CinFina Agreement with Janssen for QW Obesity AssetsPurchase Blast
$599
Posted in: Other Sep 20 | 2021Kerendia Trial Initiated in Non-T2DM CKD Patients (FIND-CKD); New Virtual Diabetes Platform LaunchedPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Sep 17 | 2021Diamyd's Ph3 T1DM Vaccine Placed on Partial Clinical Hold; Osama Hamdy Joins Nemaura Scientific Board; Medtronic Licenses Implantable Pump; Diabeloop joins the AACE Corporate Advisory Program and Appoints US Scientific AdvisorsPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Other Sep 15 | 2021Novo Nordisk Center for Genomic Mechanisms of Disease Launched; Lifescan and Welldoc Partnership; Xeris Approved to Acquire StrongBridge Pharma; Oramed Reaches 50% Enrollment in NASHPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Other, SGLT2i Sep 13 | 2021September 13-16 CHMP Agenda; Dexcom Exec Joins iRhythm as CEO; Provention Teplizumab UpdatePurchase Blast
$599
Posted in: Other Sep 10 | 2021Another Inclisiran CVOT (VICTORION-2P); Not Even in Primary PreventionPurchase Blast
$599
Posted in: Other, SGLT2i Sep 09 | 2021Jardiance Receives Breakthrough Therapy Designation for HFpEF; Metacrine Ph2a NASH Trial Completes Enrollment; Dario Signs Northeast Regional EmployerPurchase Blast
$599
Posted in: Other Sep 08 | 2021Agentix Signs WW Licensing Agreement for T2DM, NAFLD, and Obesity AssetPurchase Blast$599
Posted in: GLP-1RA, Glucose Monitoring Sep 07 | 2021Oral Sema Ph3 Obesity Program Initiated; GlucoModicum Appoints Former Dexcom Exec; Lilly Contributes to T1DM Camp InitiativePurchase Blast
$599
Posted in: Other Aug 31 | 2021Dario Selected as Digital Behavioral Health Partner for PeopleOne HealthPurchase Blast
$599
Posted in: Dual/triple agonist Aug 30 | 2021Why A Lexicon Deal for Sota Feels Like Momentum Is BuildingPurchase Blast
$599
Posted in: Other Aug 28 | 2021Finerenone Likely to Remain an Add-on to SGLT2i; FIGARO-DKD and FIDELITY Results @ ESC 2021Purchase Blast
$599
Posted in: SGLT2i Aug 27 | 2021EMPEROR-Preserved Creates a Multitude of Complex ImplicationsPurchase Blast$599
Posted in: Other Aug 26 | 2021Novo’s IL-6 Ph3 CVOT Posted to CT.gov; Additional Diamyd T1DM Vaccine AnalysesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin Aug 26 | 2021Lannett CY Q2 ‘21 (FY Q4 '21) Earnings UpdatePurchase Blast
$599
Posted in: GLP-1RA, Other Aug 25 | 2021Ph3 Icosema Trial Observed; Novel T1DM Treatment Development; DIAGNODE-3 Trial ObservedPurchase Blast